News and Events

Latest News

Stay up to date on Relief activities

Corporate News

Archive

Relief Therapeutics Announces Executive Changes

3 June 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders

30 May 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives

8 May 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics has published its Annual Report

30 April 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

27 March 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

22 March 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Renews CHF 50 million Share Subscription Facility

28 February 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

5 December 2023 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces CEO Transition

22 November 2023 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone

10 October 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Company

Pipeline

Investor Relations

News and Events

Privacy Policy

Disclaimer

Imprint

© Relief Therapeutics